4-Methylmorpholine → (S)-2-((S)-3-acetamido-3-((R)-sec-butyl)-2-oxopyrrolidin-1-yl)-N-((1R,2S)-3-(3,5-difluorophenyl)-1-hydroxy-1-((2R,4R)-4-(pyridin-3-yloxy)pyrrolidin-2-yl)propan-2-yl)-4-phenylbutanamide

HRID 132963Notizen

Reaktionsgleichung

Reaktionsgleichung von HRID 132963
[C:1]([NH:4][C@:5]1([C@@H:60]([CH2:62][CH3:63])[CH3:61])[CH2:9][CH2:8][N:7]([C@@H:10]([CH2:51][CH2:52]C2C=CC=CC=2)[C:11]([NH:13][C@@H:14]([CH2:42][C:43]2[CH:48]=[C:47]([F:49])[CH:46]=[C:45]([F:50])[CH:44]=2)[C@@H:15]([C@H:17]2[CH2:21][C@H:20]([O:22]C3C=CC=CN=3)[CH2:19][N:18]2C(C2C=CC=CC=2)C2C=CC=CC=2)[OH:16])=[O:12])[C:6]1=[O:59])(=[O:3])[CH3:2].C(N[C@]1([C@@H](CC)C)CCN([C@@H](CCC2C=CC=CC=2)C(N[C@@H](CC2C=C(F)C=C(F)C=2)[C@@H]([C@H]2C[C@@H](O[C:86]3[CH:87]=[N:88][CH:89]=[CH:90][CH:91]=3)CN2C(C2C=CC=CC=2)C2C=CC=CC=2)O)=O)C1=O)(=O)C.C(N[C@]1([C@@H](CC)C)CCN([C@@H](CC[C:142]2[CH:147]=[CH:146][CH:145]=[CH:144][CH:143]=2)C(O)=O)C1=O)(=O)C.CN(C(ON1N=NC2C=CC=NC1=2)=[N+](C)C)C.F[P-](F)(F)(F)(F)F.N[C@@H](CC1C=C(F)C=C(F)C=1)[C@@H]([C@H]1C[C@H](OC2C=CC=CN=2)CN1C(C1C=CC=CC=1)C1C=CC=CC=1)O.CN1CCOCC1>CN(C=O)C>[C:1]([NH:4][C@:5]1([C@@H:60]([CH2:62][CH3:63])[CH3:61])[CH2:9][CH2:8][N:7]([C@@H:10]([CH2:51][CH2:52][C:142]2[CH:147]=[CH:146][CH:145]=[CH:144][CH:143]=2)[C:11]([NH:13][C@@H:14]([CH2:42][C:43]2[CH:48]=[C:47]([F:49])[CH:46]=[C:45]([F:50])[CH:44]=2)[C@H:15]([OH:16])[C@H:17]2[CH2:21][C@@H:20]([O:22][C:86]3[CH:87]=[N:88][CH:89]=[CH:90][CH:91]=3)[CH2:19][NH:18]2)=[O:12])[C:6]1=[O:59])(=[O:3])[CH3:2]

Komponenten

8

Versuchsvorschrift

Step 13 (C): (S)-2-((S)-3-acetamido-3-((R)-sec-butyl)-2-oxopyrrolidin-1-yl)-N-((1S,2S)-1-((2R,4R)-1-benzhydryl-4-(pyridin-3-yloxy)pyrrolidin-2-yl)-3-(3,5-difluorophenyl)-1-hydroxypropan-2-yl)-4-phenylbutanamide. To a solution of (S)-2-((S)-3-acetamido-3-((R)-sec-butyl)-2-oxopyrrolidin-1-yl)-4-phenylbutanoic acid (Preparation A, 18.1 mg, 0.050 mmol) in DMF (1 mL) was added HATU (22.8 mg, 0.06 mmol). A solution of (1S,2S)-2-amino-1-((2R,4R)-1-benzhydryl-4-(pyridin-3-yloxy)pyrrolidin-2-yl)-3-(3,5-difluorophenyl)propan-1-ol (Step 13 (B), 25.9 mg, 0.050 mmol) in DMF (1 mL) was then added, followed by N-methylmorpholine (23 μl, 0.21 mmol). The reaction mixture was stirred at rt for 3 h. pH 4 buffer was then added to quench. The mixture was extracted with ethyl acetate. The organic phase was washed with sat. aqueous NaCl, dried (MgSO4), and concentrated in vacuo. The crude mixture was purified by reverse phase Prep HPLC to give the title compound (34 mg, 79% yield) as a clear, slightly brown glass: 1H NMR (CDCl3, 300 MHz) δ 0.89 (3H, d, J=6 Hz), 1.00 (3H, m), 1.10-1.16 (1H, m), 1.59-2.16 (1H, m), 2.37 (1H, m), 2.47-2.54 (1H, m), 2.64 (1H, m), 2.90 (3H, m), 3.11-3.13 (2H, m), 3.27 (1H, m), 3.50 (2H, m), 3.96-3.99 (3H, m), 4.30 (1H, brd s), 5.19 (1H, s), 5.43 (1H, s), 6.58-6.60 (3H, m), 6.87 (1H, m), 7.11-7.38 (10H, m), 7.56 (2H, m), 7.71 (2H, d, J=6 Hz), 7.81 (1H, m), 8.00 (1H, d, J=6 Hz), 8.40 (1H, d, J=3 Hz), 8.77 (1H, s). HPLC retention time: 1.73 min (method A). MS (ESI) (M+H)+ 858.31.

Aufarbeitung

  1. additionbuffer was then added
  2. customto quench
  3. extractionThe mixture was extracted with ethyl acetate
  4. washThe organic phase was washed with sat. aqueous NaCl
  5. dry with materialdried (MgSO4)
  6. concentrationconcentrated in vacuo
  7. customThe crude mixture was purified by reverse phase Prep HPLC

Quellen und Nachweise

ORD-Eintrag
ord-d240655d2c89401fb7e8403fe358158f
Quelldatensatz
uspto-grants-2008_06
Patentnummer
US07388007B2

Notizen zur Reaktion

Wird geladen…